Japan’s Biotechnology Industry - Porter’s Five Forces Strategy Analysis
In recent years, the Japanese government has taken measures to boost development within the biotechnology industry in the country. With increased interest from US and other international companies, the Japanese biotech market has witnessed a surge in business activity that has actively expanded the industry in last couple of years. In fact, the Abe government in 2014 announced that it is all set to establish a pilot factory for biologic drugs for the treatment of varied diseases, with particular focus on cancer.
The Japanese biotechnology industry had revenues of nearly USD 40 billion in 2014, which is expected to reach nearly USD 45 billion by the end of 2019.
In this exciting growth period of the industry, Aruvian Research analyzes the Japanese biotechnology industry in a Michael Porter's Five Forces Framework analysis to determine the competitive intensity of the industry and thus the attractiveness of this industry.
The report also includes an analysis of the Japanese biotechnology industry through an industry definition, industry statistics ranging from 2010 to 2019 (forecast), industry segmentation and an industry forecast to 2019.
The Porter's Five Forces Strategy Analysis looks at the Japanese biotech market through the bargaining power of buyers and sellers, the competitive rivalry within the industry, and the threat of new entrants in the industry. Threat of industry substitution is also analyzed in the framework.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook